Analysts Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) PT at $15.88

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) have earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $15.8750.

Several brokerages recently commented on CMPS. HC Wainwright reduced their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 4th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of COMPASS Pathways in a report on Friday, August 1st. BTIG Research boosted their price target on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Morgan Stanley increased their price objective on COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds have recently bought and sold shares of CMPS. Woodline Partners LP raised its position in shares of COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock valued at $5,019,000 after buying an additional 1,292,927 shares in the last quarter. Polar Asset Management Partners Inc. bought a new position in COMPASS Pathways in the first quarter valued at $657,000. 22NW LP purchased a new stake in COMPASS Pathways during the first quarter valued at about $1,849,000. ARK Investment Management LLC raised its position in COMPASS Pathways by 4.0% during the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock valued at $5,162,000 after purchasing an additional 68,601 shares in the last quarter. Finally, Vident Advisory LLC bought a new stake in COMPASS Pathways during the first quarter worth about $95,000. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $5.20 on Monday. The stock has a fifty day moving average of $5.87 and a 200-day moving average of $4.73. The stock has a market cap of $498.89 million, a PE ratio of -1.91 and a beta of 2.22. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $7.09.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. Equities research analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.